1-3 of 3
Marion Maetens
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial

Mattia Rediti, Danai Fimereli, Magdalena Mileva, Zéna Wimana, David Venet, Patrick Flamen, Thomas Guiot, Elisabeth G.E. de Vries, Carolien P. Schröder, Catharina Willemien Menke-van der Houven van Oordt, Marion Maetens, Samira Majjaj, Denis Larsimont, Françoise Rothé, Christos Sotiriou, Géraldine Gebhart
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 110–121.
https://doi.org/10.1158/1078-0432.CCR-24-1007
Published: 06 January 2025
View article titled, Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Open the PDF for Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial

David Venet, Mattia Rediti, Marion Maetens, Debora Fumagalli, David N. Brown, Samira Majjaj, Roberto Salgado, Lajos Pusztai, Nadia Harbeck, Sarra El-Abed, Yingbo Wang, Cristina Saura, Henry Gomez, Vladimir Fedorovich Semiglazov, Evandro de Azambuja, Jens Huober, Paolo Nuciforo, Serena Di Cosimo, Martine Piccart, Sherene Loi, Françoise Rothé, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5607–5618.
https://doi.org/10.1158/1078-0432.CCR-21-1317
Published: 15 October 2021
View article titled, Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
Open the PDF for Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

Françoise Rothé, Maria Joao Silva, David Venet, Christine Campbell, Ian Bradburry, Ghizlane Rouas, Evandro de Azambuja, Marion Maetens, Debora Fumagalli, Vanessa Rodrik-Outmezguine, Serena Di Cosimo, Daniela Rosa, Stephen Chia, Andrew Wardley, Takayuki Ueno, Wolfgang Janni, Jens Huober, Jose Baselga, Martine Piccart, Sherene Loi, Christos Sotiriou, Sarah-Jane Dawson, Michail Ignatiadis
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (12): 3581–3588.
https://doi.org/10.1158/1078-0432.CCR-18-2521
Published: 14 June 2019
View article titled, Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Open the PDF for Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial in another window
Includes: Supplementary data